Relapsing Remitting Multiple Sclerosis

Ocrelizumab Approved for Progressive, Relapsing Multiple Sclerosis

Ocrelizumab Approved for Progressive, Relapsing Multiple Sclerosis

By

The biannual infusion is approved for the treatment of adults with relapsing and progressive forms of multiple sclerosis.

Relapsing-Remitting Multiple Sclerosis Halted With Immunosuppression, Stem Cell Transplant

Relapsing-Remitting Multiple Sclerosis Halted With Immunosuppression, Stem Cell Transplant

By

Five years after treatment, nearly 70% of patients with relapsing-remitting multiple sclerosis showed no signs of disease progression.

Gray Matter, White Matter Ratio Predicts Multiple Sclerosis Progression

Gray Matter, White Matter Ratio Predicts Multiple Sclerosis Progression

By

Previous MRI studies focused on gray matter changes only.

Alemtuzumab May Reduce Disability in Early MS

Alemtuzumab May Reduce Disability in Early MS

By

The authors aimed to identify confirmed disability improvement (CDI), which reflects a clinically meaningful change in EDSS score.

Gut Bacteria Profile Differs in Patients with Multiple Sclerosis

Gut Bacteria Profile Differs in Patients with Multiple Sclerosis

By

Differences in gut bacteria were apparent between patients with active RRMS and those in remission.

Siponimod Effective in Reducing Disease Activity in Relapsing MS

Siponimod Effective in Reducing Disease Activity in Relapsing MS

By

The 2 mg dose appears to be most efficacious.

Ocrelizumab Granted Priority Review for Treatment of Multiple Sclerosis

Ocrelizumab Granted Priority Review for Treatment of Multiple Sclerosis

By

If approved, the monoclonal antibody will be the first treatment indicated for both RMS and PPMS.

Anti-LINGO-1 Fails to Meet Primary Endpoint in Multiple Sclerosis

Anti-LINGO-1 Fails to Meet Primary Endpoint in Multiple Sclerosis

By

The company said it will continue to explore its options.

Immunosuppressive Therapy Plus Stem Cell Transplant Promising in Severe RRMS

Immunosuppressive Therapy Plus Stem Cell Transplant Promising in Severe RRMS

By

Notably, results were achieved without maintenance therapy.

Fingolimod Tied to Improved Cognition in Relapsing-Remitting Multiple Sclerosis

Fingolimod Tied to Improved Cognition in Relapsing-Remitting Multiple Sclerosis

By

At follow-up, 22 patients were cognitively impaired compared to 34 at baseline.

Zinbryta Injection for Multiple Sclerosis Wins FDA Approval

Zinbryta Injection for Multiple Sclerosis Wins FDA Approval

By

The monthly injectable comes with a boxed warning for severe liver injury.

Ocrelizumab Promotes No Evidence of Disease Activity in Multiple Sclerosis

Ocrelizumab Promotes No Evidence of Disease Activity in Multiple Sclerosis

By

Treatment with the biannual injection consistently resulted in greater achievement of NEDA compared to standard care.

Interferon-Beta Safe in Early Pregnancy in Women With MS

Interferon-Beta Safe in Early Pregnancy in Women With MS

By

Women who experience relapse and take corticosteroids may be at risk for complications.

Switch to Oral Therapy Does Not Promote Multiple Sclerosis Relapse

Switch to Oral Therapy Does Not Promote Multiple Sclerosis Relapse

By

No differences were observed among the group who switched therapy and controls.

Mediation of Lipocalin-2 Suggests Therapeutic Target in Progressive MS

Mediation of Lipocalin-2 Suggests Therapeutic Target in Progressive MS

By

Combined results confirmed that intrathecal LCN2 production was increased in MS patients, especially those with SPMS and PPMS.

Tysabri Affects JC Virus Seroconversion in Multiple Sclerosis Patients

Tysabri Affects JC Virus Seroconversion in Multiple Sclerosis Patients

Natalizumab treatment linked to 15.9% increase of value in JC virus.

Beyond First-Line: Natalizumab vs Fingolimod for Relapsing-Remitting Multiple Sclerosis

Beyond First-Line: Natalizumab vs Fingolimod for Relapsing-Remitting Multiple Sclerosis

By

When first-line therapies fail, physicians must consider several factors when choosing the next course of treatment for their RRMS patients.

Targeting Depression May Help Improve Psychosocial Symptoms in MS

Targeting Depression May Help Improve Psychosocial Symptoms in MS

By

The results suggest that addressing depression may help improve other symptoms, like pain and fatigue.

Multiple Sclerosis Clinical Trials More Successful Than Other Diseases

Multiple Sclerosis Clinical Trials More Successful Than Other Diseases

By

MS clinical trials have triple the success rate of those focused on other diseases.

Sign Up for Free e-newsletters



CME Focus